457 reports of this reaction
1.3% of all ABEMACICLIB reports
#19 most reported adverse reaction
MYELOSUPPRESSION is the #19 most commonly reported adverse reaction for ABEMACICLIB, manufactured by Eli Lilly and Company. There are 457 FDA adverse event reports linking ABEMACICLIB to MYELOSUPPRESSION. This represents approximately 1.3% of all 35,479 adverse event reports for this drug.
Patients taking ABEMACICLIB who experience myelosuppression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYELOSUPPRESSION is a less commonly reported adverse event for ABEMACICLIB, but still significant enough to appear in the safety profile.
In addition to myelosuppression, the following adverse reactions have been reported for ABEMACICLIB:
The following drugs have also been linked to myelosuppression in FDA adverse event reports:
MYELOSUPPRESSION has been reported as an adverse event in 457 FDA reports for ABEMACICLIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYELOSUPPRESSION accounts for approximately 1.3% of all adverse event reports for ABEMACICLIB, making it a notable side effect.
If you experience myelosuppression while taking ABEMACICLIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.